An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

PubWeight™: 3.45‹?› | Rank: Top 1%

🔗 View Article (PMC 1766645)

Published in Gut on April 01, 1999

Associated clinical trials:

Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study | NCT02081404

Articles citing this

(truncated to the top 100)

Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut (2005) 7.35

Alarm symptoms in early diagnosis of cancer in primary care: cohort study using General Practice Research Database. BMJ (2007) 4.93

An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ (2000) 3.45

Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX). BMJ (2013) 2.28

Cough. 1: Chronic cough in adults. Thorax (2003) 1.93

Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut (2005) 1.82

Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut (2004) 1.60

Functional heartburn: the stimulus, the pain, and the brain. Gut (2002) 1.51

Management of gastro-oesophageal reflux disease in general practice. BMJ (2001) 1.48

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol (2004) 1.36

Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil (2010) 1.33

Prevalence of gastroesophageal reflux disease symptoms and uninvestigated dyspepsia in Korea: a population-based study. Dig Dis Sci (2007) 1.20

NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol (2013) 1.20

The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut (2008) 1.18

Simultaneous recordings of oesophageal acid exposure with conventional pH monitoring and a wireless system (Bravo). Gut (2005) 1.17

Nonerosive Reflux Disease (NERD) - An Update. J Neurogastroenterol Motil (2010) 1.04

Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut (2005) 1.04

Prevalence and risk factors of gastroesophageal reflux disease in Qashqai migrating nomads, southern Iran. World J Gastroenterol (2009) 1.01

Barrett's esophagus: Incidence, etiology, pathophysiology, prevention and treatment. Ther Clin Risk Manag (2007) 1.00

Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders. World J Gastroenterol (2015) 0.98

Gastroesophageal reflux disease: Update on inflammation and symptom perception. World J Gastroenterol (2013) 0.97

Current trends in the management of gastroesophageal reflux disease: a review. ISRN Gastroenterol (2012) 0.95

Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci (2002) 0.94

Dyspepsia: management guidelines for the millennium. Gut (2002) 0.93

Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients. World J Surg (2010) 0.92

Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med (2016) 0.92

Role of digital chromoendoscopy in detecting minimal change esophageal reflux disease. World J Gastrointest Endosc (2010) 0.90

Definitions of reflux disease and its separation from dyspepsia. Gut (2002) 0.90

Acid and non-acid reflux patterns in patients with erosive esophagitis and non-erosive reflux disease (NERD): a study using intraluminal impedance monitoring. Dig Dis Sci (2008) 0.90

Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes. World J Gastroenterol (2013) 0.90

Acid challenge to the human esophageal mucosa: effects on epithelial architecture in health and disease. Dig Dis Sci (2005) 0.90

Gastroesophageal reflux disease is uncommon in Asia: evidence and possible explanations. World J Gastroenterol (1999) 0.89

On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci (2004) 0.89

High prevalence of heartburn and low acid sensitivity in patients with idiopathic achalasia. Dig Dis Sci (2010) 0.89

The impact of gastroesophageal reflux disease on quality of life. Surg Endosc (2003) 0.89

A comparison of the clinical, demographic and psychiatric profiles among patients with erosive and non-erosive reflux disease in a multi-ethnic Asian country. World J Gastroenterol (2005) 0.88

Comparison of gastroesophageal reflux disease symptoms and proton pump inhibitor response using gastroesophageal reflux disease impact scale questionnaire. J Neurogastroenterol Motil (2013) 0.87

A study of the effect of nasal modes of ventilation on the incidence of gastro-oesophageal reflux in preterm neonates. Med J Armed Forces India (2012) 0.86

Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol (2008) 0.85

Heartburn and regurgitation have different impacts on life quality of patients with gastroesophageal reflux disease. World J Gastroenterol (2014) 0.85

Treatment of GORD: Three decades of progress and disappointments. United European Gastroenterol J (2013) 0.84

Esophageal histology does not provide additional useful information over clinical assessment in identifying reflux patients presenting for esophagogastroduodenoscopy. Dig Dis Sci (2000) 0.84

EAES recommendations for the management of gastroesophageal reflux disease. Surg Endosc (2014) 0.84

A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci (2006) 0.83

Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut (2004) 0.83

Prevalence of gastroesophageal reflux symptoms in a large unselected general population in Japan. World J Gastroenterol (2008) 0.83

Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol (2012) 0.82

Gastroesophageal reflux disease: medical or surgical treatment? Gastroenterol Res Pract (2009) 0.81

Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag (2007) 0.81

A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci (2006) 0.81

Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy. Dig Dis Sci (2011) 0.81

Laparoscopic Nissen fundoplication in patients with nonerosive reflux disease. Long-term quality-of-life assessment and surgical outcome. Surg Endosc (2005) 0.80

Lifestyle measures in the management of gastro-oesophageal reflux disease: clinical and pathophysiological considerations. Ther Adv Chronic Dis (2015) 0.80

Microscopic esophagitis in gastro-esophageal reflux disease: individual lesions, biopsy sampling, and clinical correlations. Virchows Arch (2008) 0.80

Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol (2016) 0.79

Effects of prior endoluminal gastroplication on subsequent laparoscopic Nissen fundoplication. Surg Endosc (2007) 0.79

Heartburn severity does not predict disease severity in patients with erosive esophagitis. MedGenMed (2006) 0.79

Pathophysiology of gastro-oesophageal reflux disease. Acta Otorhinolaryngol Ital (2006) 0.79

Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. World J Gastroenterol (2005) 0.79

Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging (2007) 0.79

A randomized, double blinded, clinical trial to assess the efficacy and cost effectiveness of omeprazole compared to rabeprazole in the maintenance therapy of patients with gastroesophageal reflux disease. J Neurogastroenterol Motil (2013) 0.79

Effect of body weight and esophageal damage on the severity of gastroesophageal reflux symptoms. Mexican GERD working group. Arch Med Res (2009) 0.78

A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease. J Gastroenterol (2008) 0.78

Helicobacter pylori Eradication Therapy in Nonulcer Dyspepsia is Beneficial. Saudi J Gastroenterol (2008) 0.78

Effects of pantoprazole 20 mg in mildgastroesophageal reflux disease: Once-daily treatment in the acute phase, and comparison of on-demand versus continuous treatment in the long term. Curr Ther Res Clin Exp (2005) 0.78

Selective-serotonin reuptake inhibitors for the treatment of hypersensitive esophagus. Therap Adv Gastroenterol (2011) 0.78

Clinical and endoscopic features of Chinese reflux esophagitis patients. World J Gastroenterol (2008) 0.77

Gastroesophageal reflux disease management according to contemporary international guidelines: a translational study. World J Gastroenterol (2011) 0.77

Presence of minimal change esophagitis closely correlates with pathological conditions in the stomach. Dig Dis Sci (2011) 0.77

It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole -- a report from a study with Japanese patients. Dig Dis Sci (2008) 0.77

Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study. World J Gastroenterol (2005) 0.77

Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease. Clin Exp Gastroenterol (2010) 0.76

i-Scan detection of minimal change esophagitis in dyspeptic patients with or without Gastroesophageal Reflux disease. BMC Gastroenterol (2016) 0.76

Managing gastroesophageal reflux disease in children: The role of endoscopy. World J Gastrointest Endosc (2012) 0.76

Impact of PPIs on patient focused symptomatology in GERD. Ther Clin Risk Manag (2008) 0.76

Acid suppression in gastro-oesophageal reflux disease: Why? How? How much and when? Postgrad Med J (2002) 0.76

Gastroesophageal Reflux Disease: An Emerging Disease in Asia. Gastroenterol Hepatol (N Y) (2006) 0.75

Helicobacter pylori and gastro-oesophageal reflux disease: important data were not presented. BMJ (2004) 0.75

Management of gastro-oesophageal reflux disease: role of proton pump inhibitor test and upper gastro-intestinal endoscopy. Acta Otorhinolaryngol Ital (2006) 0.75

Central Obesity as a Risk Factor for Non-Erosive Reflux Disease. Yonsei Med J (2017) 0.75

Impact of Helicobacter pylori infection on histological changes in non-erosive reflux disease. World J Gastroenterol (2004) 0.75

GORD in adults. BMJ Clin Evid (2008) 0.75

Gastro-oesophageal reflux disease in general practice. Last year's guidelines are probably biased. BMJ (2002) 0.75

Heartburn in Staff of Golestan Medical University, Northeast of Iran. Gastroenterology Res (2009) 0.75

Clinical usefulness of adherence to gastro-esophageal reflux disease guideline by Spanish gastroenterologists. World J Gastroenterol (2012) 0.75

Outcomes of endoluminal gastric plication for the treatment of gastroesophageal reflux disease. Proc (Bayl Univ Med Cent) (2003) 0.75

Medical treatment of gastro-oesophageal reflux disease. Acta Otorhinolaryngol Ital (2006) 0.75

Reducing dyspepsia costs in the community. Gut (2002) 0.75

Discrepancies between upper GI symptoms described by those who have them and their identification by conventional medical terminology: a survey of sufferers in four countries. Eur J Gastroenterol Hepatol (2016) 0.75

Pictograms to Provide a Better Understanding of Gastroesophageal Reflux Symptoms in Chinese Subjects. Gastroenterol Res Pract (2017) 0.75

Interobserver reproducibility in pathologist interpretation of columnar-lined esophagus. Virchows Arch (2015) 0.75

Total diet, individual meals, and their association with gastroesophageal reflux disease. Health Promot Perspect (2017) 0.75

Long-term experience of treating 185 patients with gastroesophageal reflux disease (GERD) by anti-reflux surgery respecting the functional-morphological restoration of the esophagus. Langenbecks Arch Surg (2005) 0.75

Gastroesophageal reflux disease prevalence among school teachers of Saudi Arabia and its impact on their daily life activities. Int J Health Sci (Qassim) (2017) 0.75

Supplementation of Los Angeles classification with esophageal mucosa index of hemoglobin can predict the treatment response of erosive reflux esophagitis. Surg Endosc (2011) 0.75

Endoscopic antireflux therapy. Surg Endosc (2003) 0.75

Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.". Dig Dis Sci (2005) 0.75

A prospective study of gastric acid analysis and esophageal acid exposure in patients with gastroesophageal reflux refractory to medical therapy. Dig Dis Sci (2005) 0.75

Need for guidelines in gastroenterology for the general practitioner. Dig Dis Sci (2005) 0.75

Correlation Between Symptom Severity and Health-Related Life Quality of a Population With Gastroesophageal Reflux Disease. Gastroenterology Res (2017) 0.75

Articles cited by this

(truncated to the top 100)

Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51

Does hiatus hernia affect competence of the gastroesophageal sphincter? N Engl J Med (1971) 5.44

The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology (1996) 4.69

Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology (1997) 4.59

The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology (1994) 4.35

Symptoms in gastro-oesophageal reflux disease. Lancet (1990) 4.10

Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med (1994) 4.00

A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med (1995) 3.98

Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet (1994) 3.84

Histological consequences of gastroesophageal reflux in man. Gastroenterology (1970) 3.77

Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology (1990) 3.77

Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology (1987) 3.56

The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol (1988) 3.53

Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract (1989) 3.53

Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology (1988) 3.51

A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc (1994) 3.14

The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology (1996) 3.11

The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol (1998) 3.04

The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol (1991) 2.91

Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut (1996) 2.75

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 2.64

Prevalence of metaplasia at the gastro-oesophageal junction. Lancet (1994) 2.45

Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol (1998) 2.44

Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion (1992) 2.40

Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract (1995) 2.31

The effect of raw onions on acid reflux and reflux symptoms. Am J Gastroenterol (1990) 2.19

Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol (1997) 2.17

Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology (1996) 2.14

Long-term results of a prospective randomized comparison of total fundic wrap (Nissen-Rossetti) or semifundoplication (Toupet) for gastro-oesophageal reflux. Br J Surg (1996) 2.11

Responses of consecutive patients to reassurance after gastroscopy: results of self administered questionnaire survey. BMJ (1997) 2.07

Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med (1992) 2.06

Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol (1997) 2.02

Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med (1991) 2.01

Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol (1987) 1.97

Reproducibility of ambulatory oesophageal pH monitoring. Gut (1988) 1.97

Ambulatory 24-hour esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci (1988) 1.91

Optimal thresholds, sensitivity, and specificity of long-term pH-metry for the detection of gastroesophageal reflux disease. Gastroenterology (1987) 1.88

Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med (1991) 1.77

Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology (1997) 1.75

Short segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut (1997) 1.75

A more physiological alternative to total fundoplication for the surgical correction of resistant gastro-oesophageal reflux. Br J Surg (1991) 1.73

Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut (1996) 1.71

A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology (1994) 1.70

A learning curve for laparoscopic fundoplication. Definable, avoidable, or a waste of time? Ann Surg (1996) 1.69

Laparoscopic Nissen fundoplication: where do we stand? Surg Laparosc Endosc (1997) 1.64

Cost effectiveness of detecting Barrett's cancer. Gut (1996) 1.63

Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther (1997) 1.63

Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl (1996) 1.63

Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology (1994) 1.61

A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol (1994) 1.59

Three year follow up of patients with gastrooesophageal reflux disease. Gut (1992) 1.57

The incidence of reflux oesophagitis. A study of endoscopy reports from a defined catchment area in Sweden. Scand J Gastroenterol (1993) 1.57

Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol (1997) 1.52

Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA (1997) 1.50

Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med (1992) 1.49

Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut (1994) 1.47

Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl (1993) 1.47

Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci (1997) 1.46

Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut (1995) 1.44

The predictive value of history in dyspepsia. Scand J Gastroenterol (1990) 1.42

Interobserver variation in the endoscopic diagnosis of reflux esophagitis. Scand J Gastroenterol (1993) 1.41

Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet (1987) 1.35

Laparoscopic surgery for gastro-oesophageal reflux: beyond the learning curve. Br J Surg (1996) 1.33

Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut (1994) 1.33

Patterns of acid reflux in complicated oesophagitis. Gut (1987) 1.30

One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol (1998) 1.29

A comparison of high and low fat meals on postprandial esophageal acid exposure. Am J Gastroenterol (1989) 1.28

Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut (1996) 1.28

Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy. Scand J Gastroenterol (1990) 1.26

Does endoscopy have a positive impact on quality of life in dyspepsia? Gastrointest Endosc (1998) 1.24

The physiology and philosophy of cause and effect. Gastroenterology (1994) 1.24

Evaluation of elevation of the head of the bed, bethanechol, and antacid form tablets on gastroesophageal reflux. Dig Dis Sci (1981) 1.22

Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther (1997) 1.18

H2 antagonists in the treatment of reflux oesophagitis: can physiological studies predict the response? Gut (1987) 1.17

Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. Gastroenterology (1995) 1.17

How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease? Dig Dis Sci (1995) 1.15

Long-term results of the Mark IV operation for hiatal hernia and analyses of recurrences and their treatment. J Thorac Cardiovasc Surg (1972) 1.15

Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus". Gut (1997) 1.14

Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut (1997) 1.13

Importance of reflux symptoms in functional dyspepsia. Gut (1995) 1.12

Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol (1997) 1.12

Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol (1996) 1.11

Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol (1997) 1.10

Diagnostic assessment of gastroesophageal reflux disease: what is possible vs. what is practical? Hepatogastroenterology (1992) 1.09

Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus (1997) 1.08

Diagnostic value of histology in non-erosive gastro-oesophageal reflux disease. Gut (1996) 1.08

Empiric therapy for gastroesophageal reflux disease. Arch Intern Med (1995) 1.08

Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial. Gut (1988) 1.06

Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire. Aliment Pharmacol Ther (1993) 1.05

Health care seeking by heartburn sufferers is associated with psychosocial factors. Am J Gastroenterol (1996) 1.04

Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut (1995) 1.02

Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management? Am J Gastroenterol (1997) 1.02

Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther (1993) 1.00

Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am J Gastroenterol (1988) 0.99

Is long-term esophageal pH monitoring of clinical value? Am J Gastroenterol (1989) 0.98

The effect of posture on gastroesophageal reflux event frequency and composition during fasting. Am J Gastroenterol (1996) 0.97

Long-term therapy for reflux esophagitis. N Engl J Med (1995) 0.97

Treatment versus management of gastroesophageal reflux disease. Am J Gastroenterol (1997) 0.97

Quality of Life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol Suppl (1995) 0.96

Quality of life: a reflection of symptoms and concerns. Scand J Gastroenterol Suppl (1996) 0.96